Zaltrap (aflibercept) 200 mg/8 mL concentrate for solution for infusion, 1 vial — France Zaltrap indications for metastatic colorectal cancer (MCRC) Targeted cancer therapy. Delivery of medications from Europe within 4-5 days. +380996042415 Viber, WhatsApp.
Indications for Zaltrap®
- metastatic colorectal cancer (MCRC) (in adult patients) resistant to or progressing after oxaliplatin-containing chemotherapy (Zaltrap® in combination with a regimen including irinotecan, fluorouracil, and calcium folinate (FOLFIRI)).
-
Dosage
Zaltrap® is administered intravenously as an infusion over 1 hour, followed by the FOLFIRI chemotherapy regimen.
Recommended dose Zaltrap® in combination with the FOLFIRI chemotherapy regimen is 4 mg/kg body weight.
- Trade Name:Zaltrap
- Chemical Name:Aflibersept
- Dosage:200 mg
- Quantity:1
- Form of Issue:Flacon
- Manufacturer:Sanofi
No reviews yet